The extent of alpha-synuclein aggregate accumulation in neurons varies depending on the type of neurotransmitter they release Authors: Hiroshi Kameda, Shinichiro Okamoto, Kakeru Ogasawara, Ayami Okuzumi, Nobutaka Hattori, Hiroyuki Hioki, Masato Koike Published: 2025 ABSTRACT AbstractAlpha-synuclein (aSyn) is a highly conserved 140-amino acid presynaptic protein involved in neuronal plasticity and recognized as the pathogenic protein in Parkinson’s disease. Aggregated aSyn propagates transsynaptically between neurons in vivo, impairing the cellular function of affected cells. However, it remains unclear whether aggregated aSyn propagates similarly across all neuronal cell types. In this study, we injected sonicated aSyn preformed fibrils into the striatum of mice and used immunohistochemistry to observe the intracellular localization of aSyn aggregates at designated survival times. Four weeks post-injection, numerous filamentous aggregates were detected in the striatum, neocortex, and substantia nigra. Multiple immunostaining techniques with neuronal markers, combined with electron microscopy, revealed that some filamentous aggregates accumulated in the perinuclear cytoplasm of neurons in these regions. However, quantitative analyses revealed that the number of cell bodies containing aSyn aggregates in the striatum was significantly lower than that in the neocortex or substantia nigra. Additionally, we examined aSyn aggregates in the glial cells of the striatum and found that filamentous aggregates were rarely detected, even 16 weeks post-injection. These findings suggest a cell-type preference depending on neurotransmitter identity for aSyn aggregation and propagation in vivo.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28153-9.Keywords: Alpha-synuclein, Protein aggregation, Neurodegeneration, Parkinson’s disease, Neuronal cell types, Mouse modelsSubject terms: Neuroscience, Neurology Introduction Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and is characterized by a range of motor symptoms, including tremor, muscle rigidity, immobility, and postural reflex dysfunction1. These motor deficits are associated with the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a reduced dopamine supply to the striatum1. In the brains of PD patients, intracellular aggregates known as Lewy bodies—composed primarily of alpha-synuclein (aSyn)2—are frequently observed in the substantia nigra and other specific brain regions and are thought to contribute to the degeneration of affected neurons3. aSyn is a highly conserved 140-amino acid protein located in cell bodies and presynaptic axon terminals4. Although this protein is believed to play roles in synaptic function and neural plasticity5,6, aSyn knockout mice do not exhibit significant abnormalities7, leaving the detailed functional roles of this protein largely unknown. While aSyn is normally soluble, aggregated aSyn is frequently observed in the brains of individuals with PD, dementia with Lewy bodies (DLB) and multiple system atrophy, which are collectively referred to as alpha-synucleinopathies. Aggregated aSyn propagates transsynaptically between neurons8 and exhibits neurotoxicity9, contributing to disease progression. Although aSyn aggregates propagate transsynaptically throughout the brain, the regions most affected by damage are notably selective. For instance, PD is predominantly characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta, which send projections to the striatum, while the extent of neuronal cell loss in the striatum is limited. Furthermore, an in vitro study using primary neuronal cultures demonstrated that aSyn aggregates were frequently detected in cortical neurons but were rarely observed in striatal neurons four days after the administration of aSyn preformed fibrils (PFFs)10. These findings suggest neuronal cell-type specific effects of aSyn aggregates; however, it remains unclear whether similar effects occur in vivo. In 2012, Luk et al. reported that intrastriatal injections of aSyn PFFs into wild-type mice led to transsynaptic propagation of aSyn aggregates, the loss of dopaminergic neurons in the substantia nigra pars compacta, and the emergence of motor deficits11. In the current study, using this mouse model of aSyn transmission, we observed intraneuronal aSyn aggregates in the neocortex, substantia nigra, and striatum at designated survival times. We quantified the numbers of neurons containing aSyn aggregates in these regions to assess neural cell type preferences for the propagation of aggregates. We also investigated the involvement of striatal glial cells in the propagation of aSyn aggregates. Results Regional propagation of phosphorylated aSyn (p-aSyn) aggregates To investigate the propagation of p-aSyn aggregates in the brain, we injected aSyn PFFs into the right striatum of mice. Two weeks after the injections, several filamentous aggregates were already observed in the striatum, neocortex, amygdala, and substantia nigra (Fig. 1). In contrast, p-aSyn aggregates were rarely observed in the thalamus (Fig. 1d, e). Four weeks after the injections, the numbers of the p-aSyn aggregates were increased in the striatum, neocortex, amygdala, and substantia nigra (Fig. 2). In the striatum, numerous filamentous p-aSyn aggregates were detected near the injection sites (Fig. 2b). In the neocortex, p-aSyn aggregates exhibited a laminar distribution within the motor area (Fig. 2c). To investigate the detailed distribution of p-aSyn aggregates, we conducted counterstaining with NeuroTrace, which revealed that p-aSyn aggregates were present in the upper part of layer V (Figure S1). p-aSyn aggregates were detected across the entire amygdala (Fig. 2f). In the substantia nigra, p-aSyn aggregates were primarily localized to the medial portion (Fig. 2h). Aggregates were scarcely observed in the thalamus at this stage (Fig. 2e). We also examined the distribution of p-aSyn aggregates 8 weeks after the injections (Fig. 3). As at 4 weeks post-injection, aggregates were observed in the striatum, neocortex, amygdala, and substantia nigra, but were scarcely observed in the thalamus. Sixteen weeks after the injection, aggregates were observed in the thalamus as well, comparable to other regions, consistent with previous findings11 (Fig. 4). We further verified aggregates on the side contralateral to the injection site. At all time points, filamentous aggregates were observed in the contralateral striatum, neocortex, and amygdala, whereas they were rarely detected in the contralateral thalamus or substantia nigra (Figs. 1, 2, 3 and 4). As a control experiment, we also prepared mice injected with 10 mM phosphate-buffered saline (PBS) and examined them at 16 weeks (Figure S2). Although remnants of dead cells and what appeared to be nonspecific staining were observed, no filamentous aggregates like those seen after PFFs injections were detected. Furthermore, to determine whether the p-aSyn observed in this context constituted aggregates, we performed staining with an anti-p-aSyn antibody on sections treated with proteinase K. Similar to the sections treated with PBS, p-aSyn immunoreactivity was detected in the neocortex (Figure S3). Brain distribution of p-aSyn aggregates at 2 weeks post-injection. (a–c) p-aSyn aggregates in the striatum (Str, b) and neocortex (NCx, c). (d–f) p-aSyn aggregates in the thalamus (Th, e) and amygdala (Amy, f). (g, h) p-aSyn aggregates in the substantia nigra (SN, h). Scale bar in (g) also applies to (a, d); scale bar in (h) also applies to (b, c, e, f); scale bar in the inset of (h) also applies to the insets of (b) and (c). Brain distribution of p-aSyn aggregates at 4 weeks post-injection. (a–h) Same as in Fig. 1. Scale bar in (g) also applies to (a, d); scale bar in (h) also applies to (b, c, e, f); scale bar in the inset of (c) also applies to the inset of (b). Brain distribution of p-aSyn aggregates at 8 weeks post-injection. (a–h) Same as in Fig. 1. Scale bar in (g) also applies to (a, d); scale bar in (h) also applies to (b, c, e, f); scale bar in the inset of (c) also applies to the inset of (b). Brain distribution of p-aSyn aggregates at 16 weeks post-injection. (a–h) Same as in Fig. 1. The location of p-aSyn aggregates in the substantia nigra shifted from the medial to the lateral side, which may have been influenced by variation in the injection site. Scale bar in (g) also applies to (a, d); scale bar in (h) also applies to (b, c, e, f); scale bar in the inset of (c) also applies to the inset of (b). Intracellular localization of p-aSyn aggregates Next, we investigated the intracellular localization of the aggregates in neurons. The perinuclear cytoplasm of neurons in the neocortex, substantia nigra, and striatum was visualized using anti-neuronal-specific nuclear protein (NeuN), anti-tyrosine hydroxylase (TH), and anti-dopamine- and cAMP-regulated phosphoprotein of 32 kDa (DARPP-32) antibodies, respectively. Four weeks after the injections, p-aSyn aggregates were frequently observed in the perinuclear cytoplasm of neurons in the neocortex and substantia nigra but were rarely observed in the striatum (Fig. 5a–l). Sixteen weeks after the injections, p-aSyn aggregates were detected in the perinuclear cytoplasm of neurons not only in the neocortex and substantia nigra but also in the striatum (Fig. 5m–x). The localization of aggregates in the perinuclear cytoplasm was further confirmed by immunoelectron microscopy (Fig. 6). p-aSyn aggregates in the cell bodies of neurons. (a–l) p-aSyn aggregates 4 weeks after the injections. Neuronal cell bodies in the neocortex (NCx), substantia nigra (SN), or striatum (Str) were visualized using anti-NeuN (a–d), anti-TH (e–h), or anti-DARPP-32 (i–l) antibodies, respectively. p-aSyn aggregates were observed in the cell bodies of neocortical and nigral neurons (arrowheads) but were rarely detected in the cell bodies of striatal neurons. (m–x) p-aSyn aggregates 16 weeks after the injection. Aggregates were observed not only in the cell bodies of neocortical and nigral neurons but also in the cell bodies of striatal neurons (arrowheads). The sections were counterstained with Hoechst. (y) Quantitative analysis of neuronal cell bodies containing p-aSyn aggregates. Two-way ANOVA revealed significant main effects of time (F(3,33) = 17.20, p = 6.67 × 10− 7) and region (F(2,33) = 12.26, p = 1.05 × 10− 4), but no significant interaction between time and region (F(6,33) = 0.95, p = 0.475). The significant differences in the pairwise comparisons between regions at each time point, assessed by Student’s t-test with Bonferroni correction following two-way ANOVA, are indicated as follows: *p < 0.05; **p < 0.01. The detailed results of the pairwise comparisons within each region and those between regions at each time point are provided in Tables S1 and S2, respectively. Scale bar in (x) applies to all panels. Electron-microscopic images of p-aSyn aggregates in the cell body. (a, b) p-aSyn aggregates in the neocortical section from mice fixed at 16 weeks post-injection. p-aSyn aggregates, which were labeled with silver granules, were localized in the perinuclear cytoplasm of neocortical neurons. Although the silver granules clustered along fibrous structures, these structures are not localized around any particular intracellular organelle. The cell membrane and nuclear membrane are indicated by translucent solid and dotted lines, respectively. n, cell nucleus; p, perinuclear cytoplasm. For quantitative analysis, we counted the number of neuronal cell bodies containing aggregates per unit area (Fig. 5y). Statistical analysis revealed that at 4, 8, and 16 weeks post-injection, the number of striatal cells containing aggregates was significantly lower than in the substantia nigra and neocortex (Fig. 5y; Table 1, S1, and S2). These findings suggest that, despite the short distance between the injection site and cell bodies, it takes longer for p-aSyn aggregates to accumulate in striatal neurons. Table 1The numbers of neuronal cell bodies containing p-aSyn aggregates per area [/10,000 µm2].TimeRegionStrSNNCx2 weeks0 ± 01)1.112 ± 1.1121.854 ± 1.2844 weeks0.334 ± 0.7463.893 ± 2.0816.896 ± 2.7708 weeks4.727 ± 2.74312.37 ± 6.16613.90 ± 4.49516 weeks6.118 ± 3.9918.565 ± 5.38712.79 ± 4.1061) Mean ± SD The numbers of neuronal cell bodies containing p-aSyn aggregates per area [/10,000 µm2]. 1) Mean ± SD Neural cell type accumulation of p-aSyn aggregates The generation of p-aSyn aggregates in axons depends on the accumulation of endogenous monomeric aSyn. To investigate this, we visualized endogenous aSyn, axons from the neocortex and substantia nigra, and axons of striatal neurons using anti-aSyn, anti-vesicular glutamate transporter 1 (VGluT1), anti-TH, and anti-glutamate decarboxylase (GAD)65/67 antibodies, respectively (Figure S4). Consistent with previous findings12, aSyn immunoreactivity was frequently observed in VGluT1-positive axons but rarely in GAD65/67-positive axons. aSyn immunoreactivity was also detected in TH-positive axons, indicating the accumulation of endogenous aSyn in dopaminergic axons of the substantia nigra. We confirmed that the antibody used to detect endogenous aSyn does not recognize p-aSyn (Figure S5). We further investigated whether glial cells are involved in the propagation of p-aSyn aggregates by examining the intracellular localization of p-aSyn aggregates in glial cells in the striatum (Fig. 7). Four weeks after the injection, filamentous p-aSyn aggregates were rarely observed in ionized calcium-binding adaptor protein 1 (Iba1)-positive (microglia; Fig. 7a–d), glial fibrillary acidic protein (GFAP)-positive (astrocytes Fig. 7e-h), or breast carcinoma amplified sequence 1 (BCAS1)-positive (oligodendrocytes; Fig. 7i–l) glial cells. Similarly, 16 weeks after the injections, filamentous p-aSyn aggregates were rarely detected in these glial cells (Fig. 7m–x). Rare localization of filamentous p-aSyn aggregates in glial cells. (a–l) Representative images of p-aSyn aggregates and Iba1-positive (a–d), GFAP-positive (e–h), and BCAS1-positive (i–l) glial cells in the striatum 4 weeks after the injection. Filamentous p-aSyn aggregates were rarely observed in these glial cells. (m–x) Representative images of p-aSyn aggregates and Iba1-positive (m–p), GFAP-positive (q–t), and BCAS1-positive (u–x) glial cells in the striatum 16 weeks after the injection. Similar to 4 weeks after injection, almost no accumulation of p-aSyn aggregates was observed within these glial cells. Arrowheads indicate the cell bodies of glial cells. Cell nuclei were visualized with Hoechst staining. Scale bar in (x) applies to all panels. Discussion In this study, we investigated the time course of aSyn aggregate propagation in neuronal cell bodies by injecting aSyn PFFs into the striatum of mice. We found that aSyn aggregate-containing cell bodies were frequently observed in the neocortex, substantia nigra, and striatum 16 weeks after the injection (Fig. 4). Glutamatergic neurons in the neocortex and dopaminergic neurons in the substantia nigra are known to send their axons to the striatum, and GABAergic neurons in the striatum arborize their axons in the striatum. Furthermore, neocortical cells projecting to the striatum are excitatory neurons situated in the upper portion of layer V. Our study also showed that p-aSyn aggregates were localized to the upper portion of layer V (Figure S1), which is consistent with previous reports13,14. These results indicate the retrograde propagation of aSyn aggregates. Further analysis of the number of aSyn aggregate-containing cell bodies in these regions revealed that the accumulation of aSyn aggregates occurs significantly more slowly in the cell bodies of striatal neurons than in those of neocortical and nigral neurons (Fig. 5y). In the brains of patients with DLB and PD, Lewy bodies are frequently observed in the neocortex and substantia nigra15. In contrast, neurons in the striatum exhibit relative resilience to aSyn aggregation. Our findings provide a neuronal basis for these phenomena. In the process of aSyn aggregation, pathogenic aSyn seeds are taken up by neighboring cells and recruit endogenous monomeric aSyn, leading to the formation of aSyn aggregates16. These aggregates are subsequently retrogradely transported to the cell bodies8. Thus, the efficiency of extracellular aSyn seed uptake and the availability of endogenous monomeric aSyn are critical factors for the formation of aSyn aggregates. It has been reported that aSyn PFFs are similarly taken up by primary neuronal cultures from the striatum and cortex10. However, the expression level of endogenous aSyn varies among neuronal cell types12. Glutamatergic neurons in the neocortex send their axons to the striatum, and their VGluT1-positive axon terminals frequently contain endogenous aSyn. In contrast, GABAergic neurons in the striatum arborize their axons locally, and their GAD-positive axon terminals rarely contain endogenous aSyn, which likely contributes to the slower accumulation of aSyn aggregates in the cell bodies of striatal neurons. In this study, we also observed that the axons of nigrostriatal dopaminergic neurons also contain endogenous aSyn (Figure S4), which likely explains the rapid accumulation of aSyn aggregates in the cell bodies of these neurons. Moreover, recent work by Chen et al. complements our findings by demonstrating that aSyn aggregates accumulating in intratelencephalic neurons of the motor cortex lead to marked functional consequences, including neuronal hyperexcitability, increased input resistance, and morphological alterations such as dendritic spine loss17. Their study further showed that these functional impairments were linked to downregulation of HCN channel activity, suggesting that the presence of aSyn aggregates not only marks anatomical spread but also disrupts cortical circuit function. These results collectively highlight that aSyn aggregation not only propagates in a cell-type-specific manner, as shown in our study, but also induces distinct electrophysiological dysfunction depending on the neuronal subtype and brain region. Our results showed that filamentous aSyn aggregates were rarely detected in striatal microglia (Fig. 7). Although microglia can uptake aSyn PFFs10, the expression level of aSyn in microglia is reported to be low18 and filamentous aSyn aggregates in microglia from PD brains have not been reported. In contrast, engulfment of cellular debris by microglia in PD brains is well-documented19. Our results are consistent with these reports and indicate that microglia primarily contribute to the clearance of aSyn aggregates rather than their propagation. Astrocytes can also uptake aSyn PFFs10. However, the expression level of aSyn in astrocytes remains controversial. Transcriptome and immunocytochemical analyses have shown that aSyn expression in astrocytes is significantly lower than in neurons18,20. On the other hand, aSyn was undetectable in astrocytes in paraffin sections but was detectable in vibratome sections using immunohistochemistry21. In PD brains, aSyn aggregates have been detected in astrocytes in the midbrain22. Furthermore, in vitro experiments demonstrated that aSyn can transfer from cortical astrocytes to cortical neurons23. Similarly, oligodendrocytes can uptake aSyn PFFs24 and express aSyn18. In addition, aSyn aggregates have been detected in oligodendrocytes in the midbrain of PD brains22,25. These findings suggest that aSyn aggregates can propagate via astrocytes and oligodendrocytes. In this study, filamentous aSyn aggregates were rarely detected in striatal astrocytes and oligodendrocytes at both 4 and 16 weeks after the injection. Limited evidence exists regarding the expression and aggregation of aSyn in striatal astrocytes and oligodendrocytes. Unlike in the neocortex and substantia nigra, neurons in the striatum exhibit relative resilience to aSyn aggregation. This suggests the possibility of regional differences in the roles of astrocytes and oligodendrocytes in the propagation of aSyn aggregates. These findings support the concept that neuronal cell-type-specific factors, such as endogenous aSyn expression levels and axonal projections, contribute to the differential accumulation of aggregates. However, this study has several limitations. First, our analysis was confined to selected brain regions and major neuronal populations, and it remains unclear whether similar patterns of propagation occur in other regions or cell types. Second, glial cell involvement was assessed only in the striatum, and regional variations in glial responses to aSyn pathology were not explored. Third, although we evaluated aggregate accumulation at multiple time points, the long-term trajectory of pathology and potential behavioral consequences were not addressed. Additionally, the interpretation of differential vulnerability based on endogenous aSyn levels was not supported by direct quantification of protein expression or uptake dynamics. Future research should aim to expand the analysis to a broader range of brain regions and neuronal and glial subtypes. Longitudinal studies including behavioral and neurodegenerative assessments will be crucial to determine the functional impact of aggregate propagation. Moreover, quantitative analyses of endogenous aSyn expression and uptake capacity will help clarify the molecular basis of cell-type-specific vulnerability. In conclusion, our results highlight the importance of neuronal identity in shaping the patterns of aSyn aggregate propagation and accumulation. This study provides a mechanistic basis for the selective vulnerability observed in synucleinopathies and suggests that targeting intrinsic cellular properties may offer novel therapeutic avenues for the treatment of Parkinson’s disease and related disorders. Methods Animals Experiments were conducted on 26 adult (≥ 8 weeks old) male C57BL/6 mice (Japan SLC, Hamamatsu, Japan). Mice were housed under specific pathogen-free conditions with 12/12 h light/dark cycles at Juntendo University. All animal procedures were approved by the Animal Experimental Committee of Juntendo University (Approval No. 2024264) and were performed in compliance with the guidelines for the Care and Use of Laboratory Animals, and all methods are reported in accordance with ARRIVE guidelines (https://arriveguidelines.org). Fibril formation of aSyn and its fragmentation Mouse recombinant aSyn protein (ANASPEC, Fremont, CA) at a concentration of 2.0 mg/ml was incubated at 37 °C in a shaking incubator at 1,200 rpm in PBS, pH 7.4, for 5 days. Turbidity was monitored using optical density measurements at 600 nm (OD600). After incubation, aSyn PFFs were pelleted by centrifugation at 100,000 × g for 20 min and resuspended in PBS. Prior to intracerebral injection, the PFFs were fragmented via sonication using a Sonifier 250 Advanced (Branson, Danbury, CT; 3 pulses; each pulse consisting of a 30-second ‘ON’ period and a 30-second ‘OFF’ period). Intracerebral injection of aSyn PFFs or PBS Mice were deeply anesthetized via intraperitoneal administration of medetomidine (0.3 mg/kg; Nihon Zenyaku Kogyo, Koriyama, Japan), midazolam (4 mg/kg; Sandoz, Tokyo, Japan), and butorphanol (5 mg/kg; Vetorphale®; Meiji Seika Pharma, Tokyo, Japan). The animals were then placed in a stereotaxic apparatus (SR-5M1-HT; Narishige, Tokyo, Japan) for precise intracerebral injections. Next, 2.5 µl of the aSyn PFF solution (2.0 µg/µl) or PBS was injected into the right striatum using a glass micropipette attached to a Picospritzer III (General Valve Corporation, East Hanover, NJ). The injection coordinates, determined according to the mouse brain atlas26, were 0.5 mm anterior to the bregma, 2.0 mm lateral to the midline, and 2.5 mm ventral to the surface of the dura mater. Mice were sacrificed at 2, 4, 8, or 16 weeks post-injection. Fixation and sectioning A total of 26 mice were deeply anesthetized with an intraperitoneal injection of sodium pentobarbital (200 mg/kg; Somnopentyl; Kyoritsu Seiyaku, Tokyo, Japan) and transcardially perfused with 20 ml of PBS, followed by 20 ml of 4% (w/v) paraformaldehyde and 0.05% (v/v) glutaraldehyde in 0.1 M sodium phosphate buffer (PB), pH 7.4. The brains were then removed and post-fixed for 20 h in 4% paraformaldehyde in 0.1 M PB at 4 °C. After three washes in PBS, the brains were cut into 50-µm-thick coronal sections using a VT1200S vibratome (Leica, Wetzlar, Germany). Immunoperoxidase staining and image acquisition Brain sections from mice injected with aSyn PFFs or PBS were first incubated overnight with 2.6 µg/ml rabbit anti-aSyn (phospho S129) antibody (ab51253; Abcam, Cambridge, MA), which detects p-aSyn aggregates, in PBS containing 0.3% (v/v) Triton X-100 and 1% (v/v) donkey serum (PBS-XD). After several washes in PBS containing 0.3% (v/v) Triton X-100 (PBS-X), the sections were incubated for 1 h with a biotin-conjugated donkey anti-rabbit IgG antibody (1:100 dilution; Sigma-Aldrich, St. Louis, MO) in PBS-XD, followed by rinsing with PBS-X. The sections were then incubated for 1 h with an avidin-biotinylated peroxidase complex (1:100 dilution; ABC Elite; Vector Laboratories, Burlingame, CA) in PBS-X. After an additional rinse with PBS, bound peroxidase activity was visualized by incubating the sections with 0.02% (w/v) diaminobenzidine-4HCl (DAB; Dojindo, Kumamoto, Japan) and 0.002% (v/v) hydrogen peroxide in 50 mM Tris-HCl, pH 7.6, for 20–40 min. The sections were thoroughly washed in PBS, mounted on APS-coated glass slides, air-dried, dehydrated in an ethanol series, cleared in xylene, and coverslipped. Digital images were captured using a DP72 digital camera (Olympus, Tokyo, Japan) and saved in TIFF format. Immunofluorescence labeling and image acquisition Brain sections from mice injected with aSyn PFFs were double-immunolabeled for p-aSyn and various markers, including DARPP-32, TH, NeuN, Iba1, GFAP, and BCAS1. Some sections were incubated overnight with a mixture of 13.0 µg/ml rabbit anti-aSyn (Abcam) and either 5.0 µg/ml mouse anti-NeuN antibody (Sigma-Aldrich, St. Louis, MO), 1.0 µg/ml mouse anti-DARPP-32 antibody (Santa Cruz Biotechnology, Santa Cruz, CA), or mouse anti-TH antibody (1:100 dilution; Sigma-Aldrich). Sections were then incubated for 2 h with a mixture of 20 µg/ml Alexa Fluor (AF)488-conjugated donkey anti-rabbit IgG antibody (Invitrogen, Carlsbad, CA) and 20 µg/ml AF594-conjugated donkey anti-mouse IgG antibody (Invitrogen). Other sections were incubated overnight with a mixture of 13.0 µg/ml rabbit anti-aSyn antibody (Abcam) and 3.0 µg/ml goat anti-Iba1 antibody (FUJIFILM Wako, Osaka, Japan). These sections were then incubated for 2 h with a mixture of 20 µg/ml AF488-conjugated donkey anti-rabbit IgG antibody (Invitrogen) and 20 µg/ml AF594-conjugated donkey anti-goat IgG antibody (Invitrogen). Other sections were incubated overnight with a mixture of 13.0 µg/ml rabbit anti-aSyn antibody (Abcam, Cambridge, MA) and either 1.0 µg/ml guinea pig anti-GFAP antibody (Frontier Institute), or guinea pig anti-BCAS1 antibody (1:200 dilution; Synaptic Systems, Göttingen, Germany). All incubations were performed in PBS-XD and followed by rinsing with PBS-X unless otherwise stated. Some sections were further counterstained with Hoechst 33342 (Thermo Fisher Scientific, Waltham, MA). The brain sections that were immunofluorescence-labeled were mounted onto glass slides, and coverslipped using 90% glycerol and 2.5% triethylenediamine in 20 mM Tris-HCl (pH 7.4). The samples were examined under a confocal laser-scanning microscope (TCS-SP5; Leica). The numbers of cell bodies containing p-aSyn aggregates in the neocortex, substantia nigra, and striatum were quantified. Z-stack confocal images were captured for three regions of interest (Fig. 5, total 50,055 µm2) within the substantia nigra, the motor area of the neocortex, and around the injection site (the striatum). The number of cell bodies containing p-aSyn aggregates was then calculated per unit area (10,000 µm2). Immunoelectron microscopy Brain sections from mice fixed at 16 weeks post-injection were pre-incubated for 30 min in PBS containing 20% (v/v) normal donkey serum (Jackson ImmunoResearch Laboratories, Bar Harbor, ME) and 0.3% (v/v) Photo-flo 600 (Kodak, Rochester, NY). Sections were then incubated overnight at 4 °C with 13.0 µg/ml rabbit anti-aSyn antibody (Abcam) in PBS containing 2% (v/v) normal donkey serum and 0.3% (v/v) Photo-flo 600, followed by two washes with PBS. Subsequently, the sections were incubated overnight at 4 °C with 1/100-diluted gold-conjugated goat anti-rabbit IgG antibody (Ultra-small Gold Reagent; Aurion, Wageningen, The Netherlands) in PBS containing 2% (v/v) normal donkey serum and 0.3% (v/v) Photo-flo 600. The sections were then post-fixed with 1% (w/v) glutaraldehyde in 0.1 M PB for 10 min and washed with distilled water. Gold particles were developed using a silver enhancement kit (R-GENT SE-EM; Aurion). The sections were washed with 0.1 M PB, stained with 1% (w/v) uranyl acetate in 0.1 M PB for 20 min, dehydrated, and flat-embedded in epoxy resin (Luveak 812; Nacalai Tesque, Kyoto, Japan). After polymerization, approximately 70-nm-thick ultrathin sections were cut using an ultramicrotome (UC6; Leica). The sections were stained briefly with 1% (w/v) uranyl acetate and 1% (w/v) lead citrate and observed under an electron microscope (HT7700; Hitachi, Tokyo, Japan). Statistical analysis Statistical differences in the numbers of neurons containing p-aSyn aggregates across brain regions (the striatum, the substantia nigra, and the neocortex) and time points were determined by two-way ANOVA followed by post hoc Student’s t-tests with Bonferroni correction using R27. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Supplementary Material 8 Acknowledgements We thank members of the Laboratory of Morphology and Image Analysis, Biomedical Research Core Facilities, Juntendo University Graduate School of Medicine for their invaluable technical assistance with microscopy. We are also grateful to the Center for Biomedical Research Resources at Juntendo University Graduate School of Medicine for their dedicated support with animal care. We would like to thank Editage (www.editage.com) for English language editing. This work was supported by KAKENHI (JP23K14785 to A.O.; JP24H00068 and JP21H04820 to N.H.; JP21H02592 and JP23K20044 to H.H.; JP20K07743 to M.K.) from the Japan Society for the Promotion of Science (JSPS), the Japan Agency for Medical Research and Development (AMED) (JP21dm0207112 to H.H.), Moonshot R&D from the Japan Science and Technology Agency (JST) (JPMJMS2024 to N.H. and H.H.), Fusion Oriented Research for disruptive Science and Technology (FOREST) from JST (JPMJFR231O to A.O.; JPMJFR204D to H.H.), the Ministry of Education, Culture, Sports, Science and Technology of Japan (the Private School Branding Project to N.H. and M.K). Author contributions Study concept and design: M.K. Design of experimental details: H.K. Acquisition of data: H.K., S.O., K.O. Technical and material support: A.O., N.H., H.H. Drafting and critical revision of the manuscript: H.K., M.K. Data availability The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Supplementary Material 4 Supplementary Material 5 Supplementary Material 6 Supplementary Material 7 Supplementary Material 8 Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.